Under pathological conditions such as cancer, PD-L1 is highly elevated on tumor cells and immune cells in human cancer patients and tumor-bearing mice, and binds to PD-1 to repress T cell activation, resulting in tumor cell immune escape from host immune surveillance [6,7,8,9,10,11]. This evidence concerns the gene PDCD1 and cancer.